T he contact system consists of the plasma proteins factor XII (FXII), prekallikrein, factor XI, and high-molecular-weight kininogen. 1 The step initiating activity is the conversion of FXII to its derivative enzyme FXIIa, achieved in vitro (but not yet demonstrated unequivocally in vivo) by contact with substances having a negatively charged surface. 2, 3 Human endothelial cells possess receptors for FXII 4 and high-molecular-weight kininogen. 5 Production of FXIIa creates the potential for dissemination of reactions along several pathways concerned with tissue defense and repair, 6 -11 including the conversion of plasminogen to the fibrinolytic enzyme plasmin 12 and activation of factor IX (FIX) 13 and factor VII (FVII) 14 in the coagulation system. Some of these actions have been demonstrated only in vitro, however, and their relevance for health is poorly understood.
When FXII coagulant activity (FXIIc) and FXII antigen (FXIIag) were measured in survivors of an acute myocardial infarction (MI) and healthy subjects, the former had significantly raised levels in one study 15 but not in another. 16 A clinical study reported FXIIa to be significantly higher in survivors of MI than in healthy control subjects. 17 An earlier analysis of the present study showed that FXIIa was positively and independently associated with the major conventional risk factors for coronary heart disease (CHD). 18 Here, the relations of plasma FXIIa concentration and a common (C46T) polymorphism of the FXII gene 19 with risk of CHD have been explored by prospective surveillance.
Methods

Subjects and Procedures
Details of the survey, the Second Northwick Heart Study, have been reported previously. 20 Briefly, 4600 men 50 to 61 years of age belonging to 9 general medical practices were screened for eligibil-ity. Those with evidence of MI on the ECG, a history of unstable angina, MI, regular medication with aspirin or anticoagulants, cerebrovascular disease, life-threatening malignancy, or other infrequently specified characteristics 20 were excluded, leaving 2951 for study. Recruitment began before the assay for FXIIa became available, so those measurements were made on samples stored at the first annual reexamination.
Participants attended for examination in a nonfasting state, having been requested not to smoke or undertake vigorous exercise from the midnight before. A 23-mL blood sample was taken and processed as described elsewhere. 20 Silicon-coated tubes were used to collect 4.5 mL of blood into 0.5 mL of 0.106 mol/L trisodium citrate anticoagulant and 13.5 mL into 1.5 mL of a commercial anticoagulant containing trasylol, EDTA, and a chloromethylketone thrombin inhibitor (Byk-Sangtec). Plasma levels of prothrombin fragment F 1ϩ2 in blood collected in this anticoagulant are in excellent agreement with those in samples taken into an anticoagulant mixture of acid citrate dextrose, EDTA, adenosine, and heparin. 21 A 5-mL blood sample was taken for serum.
Assays were performed on citrated plasma except when indicated. FVII coagulant activity (FVIIc) 22 and activated FVII (FVIIa) 23 were measured by 1-stage bioassay. FVII antigen (FVIIag) concentration was measured by ELISA (Novo Nordisk, Bagsvaerd). Fibrinogen concentration was measured by a thrombin-clotting method 24 with the use of a standard plasma (Immuno) calibrated against a World Health Organization (WHO) international standard (89/644). Prothrombin fragment F 1ϩ2 and fibrinopeptide A (FPA) were measured in plasma collected into the commercial anticoagulant. Plasma F 1ϩ2 was measured by double-antibody radioimmunoassay 25 and FPA was measured by commercial radioimmunoassay (Byk-Sangtec) as indexes of prothrombin and fibrinogen turnover, respectively. Plasma apparent FXIIa was measured by an ELISA with a monoclonal antibody specific for FXIIa 26 (Axis-Shield). Serum cholesterol and triglyceride concentrations were measured by automated enzyme procedures (Sigma and Wako Chemicals [Alpha Laboratories], respectively).
For apparent FXIIa, the within-person coefficient of variation of measurements made during the study was 10.5%, while the withinrun coefficient of variation of assays of split samples was 5.4%. The respective coefficients of variation for other hemostatic indexes were as follows: FVIIc, 15.0% and 2.2%; FVIIa, 23.0% and 11.1%; FVIIag, 11.1% and 3.5%; F 1ϩ2 , 25.0% and 7.6%; and FPA, 38.8% and 24.0%.
Tests were performed to determine whether the FXIIa assay was influenced by the quality of venepuncture, 20 length of sample storage at Ϫ20°C to Ϫ80°C, or the time that the sample stood at room temperature before assay.
Follow-Up and End Points
The principal end points were first CHD events defined as any of the following: (1) acute CHD, defined as sudden coronary death or fatal and non-fatal MI (History, ECG, cardiac enzymes, and pathology were assessed by an independent reviewer who classified events by WHO criteria 27 ); (2) silent MI, defined as new major Q waves on the ECG (Minnesota codes 1 1 , 1 2.1 through 1 2.7 , and 1 2.8 plus 5 1 or 5 2 ) 28 ; and (3) surgery for angina pectoris with CHD angiographically demonstrated. Acute CHD alone was a subsidiary end point.
Genotyping of the FXII C46T variant
DNA was extracted by the salting out method 29 from cells collected from blood taken into anticoagulant. With the use of published sequence information, 19 polymerase chain reaction amplification of exon 1 of the FXII gene was performed using the following primer pair to produce a fragment of 142 bp. The forward primer was 5Ј-GAT AGG CAG CTG GAC CAA CG-3Ј; the reverse primer was 5Ј-TGA TAG CGA CCC CCC AGA AC-3Ј.
The sequence surrounding the C46T polymorphism contains a naturally occurring BsaHI restriction enzyme site. The C46 wildtype sequence (GACGCC) contains this BsaHI site, which is abolished in the T46 rare variant (GATGCC). In the presence of the C allele BsaHI digestion yields fragments of 116 and 26 bp, whereas in the presence of the T allele, digestion does not occur. Digested polymerase chain reaction fragments were separated as described elsewhere. 30 
Statistical Analysis
Univariate analysis of continuous variables was by 1-way ANOVA. Variables were log transformed when needed to normalize distributions and stabilize variance. Plasma FXIIa levels were highly skewed; therefore, a Kruskal-Wallis nonparametric test was used in preference to 1-way ANOVA. Survival analysis used Cox's proportional-hazards model, with the significance of the parameters in the model assessed by log likelihood ratio test. All results were exponentiated as hazard ratios (95% CIs).
Results
Of 2951 European respondents qualifying for follow-up, 2624 were genotyped. At the first annual reexamination, 2471 genotyped respondents were seen and known to be free of a CHD event. Stored plasma for determination of FXIIa at this reexamination was available for 1745 men who were followed up beyond this point.
Plasma FXIIa concentration was not different in the 23 men with an FPA of 10 nmol/L and those with lower FPA levels (Pϭ0.16). However, although FXIIa concentrations were similar in those with satisfactory and less than satisfactory venepunctures, they appeared raised in 27 men with unsatisfactory venepunctures; the mean levels were 1.65, 1.49, and 2.07 ng/mL, respectively (Pϭ0.004). Exclusion of these 27 had no effect on the results of the statistical analysis; therefore, the findings presented are for all 1745 respondents. The assay result was not affected by storage up to 12 months or by holding samples at room temperature for up to 6 hours.
Clotting Factors and Genotype
The distribution of genotypes for FXII was in HardyWeinberg equilibrium, with frequencies as follows: CC, 56.7%; CT, 36.9%; and TT, 6.6%. The relative frequency of the T allele was 25% (95% CI, 24 to 27). Table 2 presents the distributions of age, BMI, BP, cholesterol, triglycerides, FVIIc, FXIIa, fibrinogen, F 1ϩ2 , and FPA in the 2471 subjects genotyped and free of CHD at 1 year. When these distributions were divided into thirds, clear trends to increasing FXIIa concentration were observed with increasing values of all variables (PϽ0.001 for linear trend) except F 1ϩ2 and fibrinogen concentrations. The associations of FXIIa with FVIIc and FPA were independent of cholesterol and triglyceride concentrations (rϭ0.08, Pϭ0.002 and rϭ0.19, PϽ0.0001 after adjustment, respectively). Furthermore, the associations of FXIIa with BMI, BP, cholesterol, triglycerides, FVIIc, and FPA were independent of its association with risk of CHD (PϽ0.001 after adjustment except for systolic BP, Pϭ0.005).
FXII and Conventional Risk Factors for CHD
FXII and CHD
Among the 2590 men genotyped and followed up, 139 (5.4%) had a CHD event during 16 163 person-years of surveillance, and 97(3.8%) had acute CHD. In the CC group, 74 (5.1%) of 1462 men had a CHD event compared with 60 (6.3%) of 969 in the CT group and 5 (3.0%) of 169 with the TT genotype. In a Cox proportional-hazards model with TT as the reference group, the hazard ratio did not differ significantly between groups (Pϭ0.12). These findings were essentially unchanged when the analysis was repeated on acute CHD alone.
In the 1745 men who were genotyped, had FXIIa determined, and were followed up, 92 (5.3%) had a CHD event and 56 (3.2%) had acute CHD. Median (interquartile range) FXIIa was 2.0 ng/mL (1.4 to 2.4 ng/mL) in the group of 92 compared with 1.7 ng/mL (1.2 to 2.2 ng/mL) in those remaining free of the disorder (Pϭ0.005, Kruskal-Wallis test). Incidence rates of CHD per 1000 person-years by thirds of the distribution of FXIIa were as follows: low (Ͻ1.5 ng/mL), 7.2; middle, 7.2; and high (Ͼ2.0 ng/mL), 13.6. The respective hazard ratios with the low third as reference group were 1.01 (95% CI, 0.58 to 1.77) and 1.96 (95% CI, 1.20 to 3.20) (Pϭ0.007, likelihood ratio test). Thus, there was strong evidence for an increased risk of CHD when FXIIa was Ͼ2.0 ng/mL. Table 3 shows that the estimate of hazard in the high third remained significantly increased after adjustment for genotype in a multivariate Cox model, whereas genotype was unrelated to risk when FXIIa was taken into account. After allowance for genotype, cholesterol, triglycerides, fibrinogen, FVIIc, FPA, systolic BP, and BMI, the adjusted hazard ratios in the middle and high thirds of FXIIa (relative to low third) were 1.03 (95% CI, 0.56 to 1.90) and 2.05 (95% CI, 1.11 to 3.75; Pϭ0.02), respectively. For acute CHD alone, the respective estimates were 1.06 (95% CI, 0.51 to 2.19) and 2.14 (95% CI, 1.13 to 4.04; Pϭ0.03).
Discussion
The assay of apparent FXIIa appeared to be affected by an unsatisfactory venepuncture, but inclusion of these results did not alter the findings of the statistical analysis. With respect to sample handling, storage up to 12 months and standing at room temperature for up to 6 hours did not affect FXIIa concentration. Thus, although samples were collected with venepunctures of differing quality (93% were coded satisfactory) and stored frozen for varying periods, collection and handling procedures appeared not to have introduced errors that could lead to misinterpretation of the findings.
As reported by others, 19,31 the CC genotype was associated with a significantly higher FXIIa concentration than homozygosity for the rare allele of the FXII genotype (TT). The C-T change creates a novel AUG methionine start-of-translation codon upstream of the correct AUG site, shown in vitro to result in less efficient translation of the T-mRNA compared with the C-mRMA. 19 Unimpaired translation in the CC genotype results in relatively high FXII and FXIIa levels.
Novel findings in this study were the significantly lower levels of FVIIc and FPA in the FXII TT genotype compared with the CT and CC groups. On average, FVIIa was 27% lower in the TT group than the CC group (Pϭ0.055). Studies in vitro have shown activation of FVII by FXIIa, 14 but whether the same occurs in vivo is uncertain. Although the higher FVIIc and FVIIa levels in the CC group, who had the higher FXIIa levels, could have occurred by chance, they may indicate that the genotypically determined status of FXII has consequences for FVII activity in vivo. This conclusion agrees with findings in patients with hereditary angioedema, in whom C1 inhibitor is very low and the contact system is activated. Plasma FVIIa concentrations in such patients are significantly higher than in healthy control subjects, suggesting modest yet biologically important activation of FVII when FXIIa activity is raised. 32 Furthermore, activation of FVII has been observed in rhesus monkeys after implantation of a porous chamber containing immobilized human FXIIa. 33 The strong association between FXIIa and FPA levels, according to FXII genotype, suggested that an increase in FXIIa has consequences for the cleavage of FPA from fibrinogen. Unexpectedly, this effect was not accompanied by any increase in F 1ϩ2 . Although there are no data within the study to address this observation further, the paradox could be explained by a reduction in antithrombin, which would result in lengthening of the half-life of thrombin. Similar apparent discrepancies have been observed in other studies. For example, in patients who suffered an acute MI but did not receive heparin, fibrin monomer was increased on the second day after the event in those who died or had a new MI within 90 days, whereas F 1ϩ2 concentration was normal at this time point. 34 The genotype for FXII determines FXII concentration and therefore will contribute to the FXIIa level by mass action. This study has also shown that serum cholesterol and triglyceride concentrations account for some additional variability in FXIIa. Thus, plasma FXIIa concentration appears to be determined partly by FXII genotype, partly by plasma lipid levels, and partly by nonlipid factors that explain its association with CHD. The independent association of FXIIa with CHD and its relations with several major CHD risk factors suggested that FXIIa concentration serves as a marker of the extent and severity of atherosclerosis. Coppola et al 35 reported a marked increase in FXIIa in patients with MI who had received thrombolytic therapy. Kohler et al 17 found FXIIa concentration to be strongly associated with the extent of coronary artery stenosis.
The origin of an increased FXIIa in men at high risk of CHD is uncertain. One possible mechanism might be that activation of vascular endothelium or other cells involved in the atherosclerotic process enhances FXII activation. This would help explain why a low FXIIa concentration is not protective against CHD; increased concentrations are primarily a consequence rather than a cause of underlying vascular disease, although high FXIIa levels may conceivably play a secondary role in the disease process.
Six percent of men were of the TT genotype. Compared with the CC and CT genotypes, TT carried a crude hazard ratio of 0.42, although with a wide 95% CI (0.13 to 1.35), and in a Cox proportional-hazards model, there was no significant difference in risk of CHD by genotype. Larger studies are needed to state with confidence whether the TT genotype confers protection against CHD because of its relatively infrequent association with a high FXIIa concentration. However, if as suggested a high FXIIa level is an effect rather than a cause of the underlying pathology in CHD, such an inherited form of protection would seem a remote possibility.
